Figure 3. A) Reprojection positron emission tomography imaging in a patient with well differentiated thyroid cancer, metastatic to the lungs, regional neck nodes and also suspected metastases in the scapula and T-12 vertebrae. At the time of imaging, thyroglobulin levels >11,000 ng/mL; estimated dose from 250 mCi of 131I estimated at >50,000 cGy; follow-up at 13 years post-multiple 131I treatments (1500 mCi total), TG <0.2, complete clinical response. B) MSKCC (Finn) target system, used to manufacture 124I. Tellurium-124.) 15 MeV protons. 124I can be produced in significant quantities by modern hospital and radiopharmacy based cyclotrons.
